Sangamo Therapeutics Inc (SGMO)
0.522
-0.02
(-4.01%)
USD |
NASDAQ |
May 02, 16:00
0.521
0.00 (0.00%)
After-Hours: 20:00
Sangamo Therapeutics Revenue (Quarterly): 2.042M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.042M |
| September 30, 2023 | 9.398M |
| June 30, 2023 | 6.835M |
| March 31, 2023 | 157.96M |
| December 31, 2022 | 27.23M |
| September 30, 2022 | 26.46M |
| June 30, 2022 | 29.38M |
| March 31, 2022 | 28.23M |
| December 31, 2021 | 27.99M |
| September 30, 2021 | 28.56M |
| June 30, 2021 | 27.87M |
| March 31, 2021 | 26.28M |
| December 31, 2020 | 25.80M |
| September 30, 2020 | 57.76M |
| June 30, 2020 | 21.55M |
| March 31, 2020 | 13.08M |
| December 31, 2019 | 54.85M |
| September 30, 2019 | 21.96M |
| June 30, 2019 | 17.55M |
| March 31, 2019 | 8.071M |
| December 31, 2018 | 26.84M |
| September 30, 2018 | 23.56M |
| June 30, 2018 | 21.42M |
| March 31, 2018 | 12.64M |
| December 31, 2017 | 13.08M |
| Date | Value |
|---|---|
| September 30, 2017 | 11.81M |
| June 30, 2017 | 8.253M |
| March 31, 2017 | 3.425M |
| December 31, 2016 | 8.922M |
| September 30, 2016 | 2.823M |
| June 30, 2016 | 3.702M |
| March 31, 2016 | 3.942M |
| December 31, 2015 | 9.121M |
| September 30, 2015 | 8.569M |
| June 30, 2015 | 8.358M |
| March 31, 2015 | 13.49M |
| December 31, 2014 | 14.95M |
| September 30, 2014 | 12.42M |
| June 30, 2014 | 10.38M |
| March 31, 2014 | 8.116M |
| December 31, 2013 | 6.869M |
| September 30, 2013 | 5.707M |
| June 30, 2013 | 6.934M |
| March 31, 2013 | 4.623M |
| December 31, 2012 | 8.932M |
| September 30, 2012 | 4.907M |
| June 30, 2012 | 4.574M |
| March 31, 2012 | 3.242M |
| December 31, 2011 | 4.748M |
| September 30, 2011 | 1.857M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.042M
Minimum
Dec 2023
157.96M
Maximum
Mar 2023
32.15M
Average
26.46M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 0.065M |
| Perspective Therapeutics Inc | -5.239M |
| Protalix BioTherapeutics Inc | 10.49M |
| Electromed Inc | 13.69M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -60.30M |
| Total Expenses (Quarterly) | 63.80M |
| EPS Diluted (Quarterly) | -0.34 |
| Enterprise Value | 12.39M |
| Profit Margin (Quarterly) | -2.95K% |
| Earnings Yield | -281.6% |
| Normalized Earnings Yield | -123.80 |